Table 2.
NF-κB staining and clinical outcomes
| Pre-treatment | Post-treatment initiation | |||||
|---|---|---|---|---|---|---|
| Characteristic | NF-κB positive1 | NF-κB negative2 | p-value | NF-κB positive1 | NF-κB negative2 | p-value |
| Overall Survival | ||||||
| Alive | 0 | 8 | .06 | 4 | 4 | .11 |
| Dead | 3 | 5 | 1 | 7 | ||
| Disease-specific Survival | ||||||
| Alive | 0 | 9 | .03 | 4 | 5 | .20 |
| Dead | 3 | 4 | 1 | 6 | ||
| Distant Metastases | ||||||
| Yes | 3 | 5 | .06 | 2 | 6 | .59 |
| No | 0 | 8 | 3 | 5 | ||
| Local-regional Failure3 | ||||||
| Yes | 3 | 3 | .01 | 0 | 6 | .04 |
| No | 0 | 10 | 5 | 5 | ||
1
positive includes moderate or strong nuclear staining
2
negative includes absent or weak nuclear staining
3
local-regional includes central, pelvic, and para-aortic relapses